| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/TP.0B013E3182888DB6 |
| P8608 | Fatcat ID | release_yj322lmoebeozbzpysriqtayr4 |
| P698 | PubMed publication ID | 23514959 |
| P50 | author | Paul Terasaki | Q7153959 |
| P2093 | author name string | Matthew Everly | |
| Anh Nguyen | |||
| Scott A Kendrick | |||
| William T Kendrick | |||
| Maria Cecilia S Freitas | |||
| Paul Bolin | |||
| Miyuki Ozawa | |||
| Carl E Haisch | |||
| Lorita M Rebellato | |||
| Kimberly P Briley | |||
| Karen Parker | |||
| Nori Sasaki | |||
| Robert C Harland | |||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 1113-1119 | |
| P577 | publication date | 2013-05-01 | |
| P1433 | published in | Transplantation | Q15730500 |
| P1476 | title | The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes | |
| P478 | volume | 95 |
| Q36302476 | An Anti-C1s Monoclonal, TNT003, Inhibits Complement Activation Induced by Antibodies Against HLA |
| Q50451727 | Anti-HLA sensitization in extensively burned patients: extent, associated factors, and reduction in potential access to vascularized composite allotransplantation. |
| Q38481656 | Anti-human leukocyte antigen DQ antibodies in renal transplantation: Are we underestimating the most frequent donor specific alloantibodies? |
| Q28076193 | Antibody Subclass Repertoire and Graft Outcome Following Solid Organ Transplantation |
| Q44425562 | Antibody-Mediated Rejection in Lung Transplantation: Clinical Outcomes and Donor-Specific Antibody Characteristics |
| Q38169496 | Antibody-mediated graft injury: complement-dependent and complement-independent mechanisms. |
| Q39366396 | Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies |
| Q36380010 | Application and interpretation of histocompatibility data in pediatric kidney transplantation. |
| Q51545660 | Association of C1q Binding Status With De Novo HLA Antibody Clinical Features and Allograft Function in Kidney Transplantation Patients During Eight Years of Dynamic Follow-up. |
| Q87395286 | Association of C1q-fixing DSA with late graft failure in pediatric renal transplant recipients |
| Q34753440 | Autologous bone marrow derived mesenchymal stromal cell therapy in combination with everolimus to preserve renal structure and function in renal transplant recipients |
| Q38282840 | Better understanding of transplant glomerulopathy secondary to chronic antibody-mediated rejection |
| Q37263143 | C1Q Assay Results in Complement-Dependent Cytotoxicity Crossmatch Negative Renal Transplant Candidates with Donor-Specific Antibodies: High Specificity but Low Sensitivity When Predicting Flow Crossmatch |
| Q50073449 | Chronic Rejection After Intestinal Transplant: Where Are We in Order to Avert It? |
| Q90450246 | Circulating B Cells With Memory and Antibody-Secreting Phenotypes Are Detectable in Pediatric Kidney Transplant Recipients Before the Development of Antibody-Mediated Rejection |
| Q36822826 | Clinical Significance of HLA-DQ Antibodies in the Development of Chronic Antibody-Mediated Rejection and Allograft Failure in Kidney Transplant Recipients. |
| Q52586350 | Clinical Utility of Complement-Dependent C3d Assay in Kidney Recipients Presenting with Late Allograft Dysfunction. |
| Q59807564 | Clinical impact of complement (C1q, C3d) binding De Novo donor-specific HLA antibody in kidney transplant recipients |
| Q38265563 | Clinical relevance of HLA antibody monitoring after kidney transplantation |
| Q48371099 | Clinical utility of C3d binding donor-specific anti-human leukocyte antigen antibody detection by single antigen beads after kidney transplantation-a retrospective study. |
| Q38217273 | Complement as a multifaceted modulator of kidney transplant injury |
| Q46970385 | Complement-Activating Anti-HLA Antibodies in Kidney Transplantation: Allograft Gene Expression Profiling and Response to Treatment |
| Q54969814 | Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: A systematic review and meta-analysis. |
| Q39928595 | De Novo DQ Donor-Specific Antibodies Are Associated with Chronic Lung Allograft Dysfunction after Lung Transplantation |
| Q40468571 | De novo donor-specific anti-HLA antibodies after kidney transplantation are associated with impaired graft outcome independently of their C1q-binding ability. |
| Q35027253 | Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss. |
| Q38204851 | Detection of donor-specific antibodies in kidney transplantation |
| Q48255248 | Determining donor-specific antibody C1q-binding ability improves the prediction of antibody-mediated rejection in human leucocyte antigen-incompatible kidney transplantation |
| Q34841849 | Diagnosis and management of antibody-mediated rejection: current status and novel approaches |
| Q97518750 | Distribution of de novo Donor-Specific Antibody Subclasses Quantified by Mass Spectrometry: High IgG3 Proportion Is Associated With Antibody-Mediated Rejection Occurrence and Severity |
| Q39265221 | Donor-Specific Antibodies in Kidney Transplant Recipients |
| Q88972270 | Donor-specific Antibody Surveillance and Graft Outcomes in Pediatric Kidney Transplant Recipients |
| Q39512442 | Eculizumab Therapy for Chronic Antibody-Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial. |
| Q26995453 | Effects of complement activation on allograft injury |
| Q99371223 | Effects of re-augmenting maintenance immunosuppression on post-transplant donor-specific HLA antibodies in liver transplantation |
| Q51563025 | Evaluation of C1q Status and Titer of De Novo Donor-Specific Antibodies as Predictors of Allograft Survival. |
| Q46516137 | Five-year histological and serological follow-up of operationally tolerant pediatric liver transplant recipients enrolled in WISP-R. |
| Q37590820 | From Humoral Theory to Performant Risk Stratification in Kidney Transplantation. |
| Q88446332 | HLA-DQ Mismatching and Kidney Transplant Outcomes |
| Q47736092 | Harnessing Scientific and Technological Advances to Improve Equity in Kidney Allocation Policies. |
| Q51591178 | Human Pooled Immunoglobulin as Treatment of Active Antibody-Mediated Rejection of Transplanted Kidney. |
| Q38341785 | Humoral immunity in renal transplantation: epitopes, Cw and DP, and complement-activating capability--an update |
| Q49813842 | Ibrutinib suppresses alloantibody responses in a mouse model of allosensitization |
| Q53076848 | Incidence and impact of anti-HLA-DP antibodies in renal transplantation. |
| Q53603593 | Influence of de novo donor-specific antibody on early renal allograft function recovery. |
| Q38341632 | Innate immunity in solid organ transplantation: an update and therapeutic opportunities |
| Q36007256 | Interpreting Anti-HLA Antibody Testing Data: A Practical Guide for Physicians |
| Q99413308 | Investigating the relationship between class I HLA-specific immunoglobulin-G subclasses, Pan-IgG single antigen bead assays and complement mediated interference in sera from renal transplant recipients |
| Q52310243 | Kidney Transplantation: The Challenge of Human Leukocyte Antigen and Its Therapeutic Strategies. |
| Q38262909 | Methodological aspects of anti-human leukocyte antigen antibody analysis in solid organ transplantation |
| Q33419651 | Molecules Great and Small: The Complement System |
| Q27314948 | Monocyte recruitment by HLA IgG-activated endothelium: the relationship between IgG subclass and FcγRIIa polymorphisms |
| Q36514864 | Non-Complement-Binding De Novo Donor-Specific Anti-HLA Antibodies and Kidney Allograft Survival. |
| Q38645385 | Potential Roles for C1 Inhibitor in Transplantation |
| Q90240618 | Predicting kidney transplant outcomes with partial knowledge of HLA mismatch |
| Q51545622 | Prediction of Complement-Binding Capacity of HLA Antibodies Based on Mean Fluorescence Intensity. |
| Q63866084 | Pretransplant C3d-Fixing Donor-Specific Anti-HLA Antibodies Are Not Associated with Increased Risk for Kidney Graft Failure |
| Q40330667 | Racial differences in incident de novo donor-specific anti-HLA antibody among primary renal allograft recipients: results from a single center cohort study |
| Q39989120 | Re-Examining Risk of Repeated HLA Mismatch in Kidney Transplantation. |
| Q36246918 | Safety of allogeneic bone marrow derived mesenchymal stromal cell therapy in renal transplant recipients: the neptune study |
| Q38558820 | Sensitization assessment before kidney transplantation |
| Q51015580 | Survival in sensitized lung transplant recipients with perioperative desensitization. |
| Q38878037 | Tac-MMF Versus CsA-MMF/CsA-AZA-Based Regimens in Development of De Novo Complement-Binding Anti-HLA Antibodies After Kidney Transplantation. |
| Q33760357 | Technical Limitations of the C1q Single-Antigen Bead Assay to Detect Complement Binding HLA-Specific Antibodies. |
| Q88656410 | The Approach to Antibodies After Heart Transplantation |
| Q57521747 | The Clinical Spectrum ofDe NovoDonor-Specific Antibodies in Pediatric Renal Transplant Recipients |
| Q26774993 | The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients |
| Q51010023 | The Value of Protocol Biopsies to Identify Patients With De Novo Donor-Specific Antibody at High Risk for Allograft Loss. |
| Q38258153 | The increasing clinical importance of alloantibodies in kidney transplantation |
| Q26862195 | The perfect storm: HLA antibodies, complement, FcγRs, and endothelium in transplant rejection |
| Q41150961 | The prevalence and clinical significance of C1q-binding donor-specific anti-HLA antibodies early and late after kidney transplantation |
| Q33877558 | Transplantation: Complementing donor-specific antibody testing |
| Q34495912 | Transplanting the elderly: Balancing aging with histocompatibility. |
| Q90344464 | Trough Level of Mycophenolic Acid Did Not Affect De Novo DSA Development in Kidney Transplantation |
| Q35790601 | Utility of HLA Antibody Testing in Kidney Transplantation |
| Q38818479 | mTOR inhibitors and risk of chronic antibody-mediated rejection after kidney transplantation: where are we now? |
Search more.